Subscribe to Newsletter
Subspecialties Glaucoma, Basic & Translational Research, Imaging & Diagnostics, Health Economics and Policy

Unraveling Glaucoma’s Genetic Tapestry

Glaucoma has long been recognized as a disease underpinned by a complex interplay of genetic and environmental factors. Over the past 25 years, the field of glaucoma genetics has evolved from constructing glaucoma family trees for gene discovery using linkage analysis and gene screening, through to large population and cohort studies for genome-wide association studies (GWAS) and developing polygenic risk scores – all of which could have profound implications for clinical practice.

At the outset, our understanding of glaucoma genetics was anchored by identifying specific genes with Mendelian inheritance patterns, such as myocilin and CYP1B1. These discoveries, heralded as breakthroughs at the time, offered valuable insights into the genetic underpinnings of the disease. Myocilin genetic testing in families could identify those carrying mutations and at high risk of developing glaucoma, and even today we are still weighing evidence as to whether one of hundreds of variations in myocilin are disease-causing mutations, benign polymorphisms, or variants of unknown significance (1).

Relatively early on, it became apparent that the Mendelian genes accounted for only a fraction of glaucoma cases. The advent of GWAS established a new era in glaucoma genetics, enabling researchers to cast a wider net in their quest for genetic determinants of the disease. Through GWAS, hundreds of genetic loci associated with glaucoma have now been discovered. From the LOXL1 gene implicated in exfoliation glaucoma, to the TMCO1 and CDKN2BAS genes linked to primary open-angle glaucoma (POAG), the genetic landscape for glaucoma has expanded exponentially, with hundreds of genes contributing to the polygenic nature of POAG (2).

Polygenic risk scores have emerged as a powerful tool in the armamentarium of glaucoma genetics; indeed, an individual’s risk score provides a nuanced assessment of genetic susceptibility to the disease. By integrating information from multiple genetic variants, a polygenic risk score can provide personalized risk estimates, enabling more targeted approaches to screening, prevention, and treatment (3). However, the utility of these scores hinge on their validation across diverse populations; notably, most studies to date have predominantly focused on Northern European cohorts.

NEWS

The Ophthalmologist Presents:

The Ophthalmologist Weekly Newsletter

Enjoying yourself? There's plenty more where that came from! Our weekly newsletter from The Ophthalmologist brings you the most popular stories as they unfold, chosen by our fantastic Editorial team!

Register for our weekly newsletter

Taking this into account, it is important to note that ethnic diversity in genetic studies is paramount for ensuring the generalizability and equitable application of genetic findings. Despite the disproportionate burden of glaucoma among individuals of African ancestry, their representation in genetic research remains inadequate  – a fact that highlights systemic disparities in research funding and participation. As such, efforts to address these disparities are imperative to guarantee that genetic insights are applicable across diverse populations, so that they can inform tailored approaches to glaucoma management – wherever it is most needed (4).

In the clinical arena, the integration of genetic information could revolutionize patient care. From risk stratification to personalized treatment algorithms, genetics has the potential to usher in a new era of precision medicine in glaucoma. But challenges abound – from the interpretation of genetic variants to the ethical implications of genetic testing and counseling.

With all of these factors to consider, several key questions loom large in the glaucoma genetics space: How do we translate genetic discoveries into actionable insights for clinical practice? What are the implications of genetic testing for disease screening and management? And how do we ensure equitable access to genetic testing and its benefits across diverse populations?

If we’re able to answer these questions, collaborations between glaucoma geneticists, researchers, and clinicians could help us achieve a realistic future in which there are no cases of glaucoma-associated blindness.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. KP Burdon et al., “Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel,” Hum Mutat, 43, 2170 (2022). PMID: 36217948.
  2. P Gharahkhani et al., “Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries,” Nat Commun, 12, 1258 (2021). PMID: 33627673.
  3. JE Craig JE et al., “Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression,” Nat Genet, 52, 160 (2020). PMID: 31959993.
  4. DA Mackey, SE Staffieri, “Making glaucoma genetic studies more diverse,” Cell, 187, 273 (2024). PMID: 38242084.
About the Author
David Mackey

David Mackey is an ophthalmologist who has worked on glaucoma genetics for thirty years since he started the Glaucoma Inheritance Study in Tasmania (GIST) in 1994. He has been involved in most of the major glaucoma genetics discoveries in this time, with over 150 publications on glaucoma genetics from over 500 papers, and he has an H index of 97 on Google Scholar. He is the chair of the monthly International Glaucoma Genetics Consortium teleconferences.

He is Vice President of the Asia Pacific Academy of Ophthalmology, Councillor for the Australian Academy of Health and Medical Sciences, Councillor of the Royal Australian and New Zealand College of Ophthalmology and in 2019 was awarded an Officer in the Order of Australia.

Related Case Studies
Business & Profession Glaucoma
TrabEx Pro: The Next Level in MIGS

| Contributed by MST

Finding Ocular Surface Inflammation

| Contributed by Quidel

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: